go-v.orgdoi

Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy

Guo-Tong Xu · Frontiers in Bioscience-Elite · 2010

  • DOI 10.2741/e151
  • Publisher Frontiers Media
  • Type article
  • Issued 2010

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Frontiers in Bioscience-Elite · Frontiers Media · article · 2010

Abstract

In the present study, a single intravitreal erythropoietin (EPO) to diabetic rats produced therapeutic effects on blood-retinal barrier (BRB) function and neuronal survival at different time courses of retinopathy. In parallel, the hypoxia-inducible factor 1 alpha (HIF-1 alpha) pathway has been quantitatively studied, including VEGF-A, endogenous EPO, EPO receptor (EpoR), prolyl hydroxylases (PHD1-3) and von Hippel-Lindau tumor suppressor (VHL). The mRNA levels of HIF-1 alpha, VEGF-A, endogenous EPO, PHD1-3 and VHL are all up-regulated in the diabetic retina, and suppressed by exogenous EPO.

The increased protein levels of HIF-1 alpha, VEGF-A, and endogenous EPO found in diabetic retinas also have been down-regulated by exogenous EPO. The results demonstrate that the HIF-1 pathway is activated in the retina in early diabetes, but is negatively regulated by a feedback loop following the administration of exogenous EPO. Exogenous EPO at pharmacologic levels leads to suppression of VEGF and in turn, restoration of the normal functions of BRB in a time-dependent manner. In the diabetic retina, the same level of exogenous EPO that inhibits VEGF also exerted neuronal protection.

Open the resolved locator · 10.2741/e151

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:33 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.2741/e151
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.